Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, has announced the availability of SARS-CoV-2 neutralizing antibodies derived from people infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for diagnostic research and development of COVID-19. They are now available to diagnostic scientists and developers around the world through the Absolute Antibody online catalog.
The new antibodies were generated from the blood cells of a COVID-19-infected patient and have been shown in a recent article to show neutralizing activity against SARS-CoV-2, the coronavirus that causes COVID-19. Two antibody clones (CV1 and CV30) each bound to the SARS-CoV-2 spike glycoprotein, and CV30 was also shown to bind to the receptor-binding domain (RBD) and inhibit interaction with the ACE2 receptor of the host cell. Both antibodies are now available in a variety of species, isotypes, and subtypes designed to extend their usefulness in COVID-19 applications.
Absolute Antibody offers SARS-CoV-2 antibodies in human formats such as IgG1, IgG3, IgM, and IgA, for use in neutralization assays and as serological controls in COVID-19 diagnostic tests. Furthermore, the antibodies are available in species such as the mouse and rabbit for detection applications and co-labeling studies; fragment formats for improved tissue penetration and in vivo imaging; and with Fc Silent ™ domains designed to facilitate the investigation of antibody-dependent enhancement. All antibodies are recombinantly produced to ensure batch-to-batch reproducibility, high purity, and low endotoxin levels.
“Since the beginning of the COVID-19 pandemic, our team has been working hard to bring engineered coronavirus antibodies to scientists around the world,” said Amelia Gibson, Ph.D., MBA, senior director of product licensing at Absolute Antibody.
“By obtaining the antibody license from the prestigious Fred Hutchinson Cancer Research Center, we are now able to supply antibodies derived from patients infected with COVID-19, a unique tool that can provide valuable information on coronavirus disease and help design better tests for diagnosis”.
The new neutralizing antibodies join Absolute Antibody’s complete collection of modified coronavirus reagents, including peak glycoprotein antibody clone CR3022, nucleoprotein antibodies, ACE2 Fc fusion proteins, and anti-human immunoglobulin antibodies for use in testing for diagnosis. Absolute Antibody also supports coronavirus research by providing antibody manufacturing and engineering services, including producing gram quantities of sequenced human antibodies from recovering COVID-19 patients.